p53 is a tumor suppressor gene, which is activated in response to several forms of cellular stress and exerts multiple antiproliferative functions, making it the most frequent target for genetic alteration in cancer. Various studies have evaluated the association between p53 codon 72 G > C (rs1042522) polymorphism and risk of cancer. However, results from the published studies remained inconclusive. The aim of this study is to investigate the precise association between this variant and a risk of cancer in a large-scale meta-analysis. We searched the PubMed (MEDLINE) and Google Scholar web databases for studies regarding the association of p53 codon 72 G > C polymorphism and risk of cancer in the Indian population. Pooled odds ratio (OR) with 95 % confidence interval (CI) were calculated by using random effect model to assess the association. Twenty studies with 3,258 cancer cases and 4,260 healthy controls were included. Overall, no significant association was detected for C allele carrier (C vs. G: OR = 1.135, 95 % CI = 0.930 to 1.386, p = 0.211) and homozygous (CC vs. GG: OR = 1.200, 95 % CI = 0.810 to 1.779, p = 0.364), heterozygous (CG vs. GG: OR = 1.204, 95 % CI = 0.921 to 1.575, p = 0.175), dominant (CC + CG vs. GG: OR = 1.231, 95 % CI = 0.932 to 1.625, p = 0.144), and recessive (CC vs. GG + GC: OR = 1.078, 95 % CI = 0.792 to 1.468, p = 0.632) genetic models, respectively. No significant publication bias was observed by using Begg's funnel plot and Egger's test. Present meta-analysis indicated that the p53 codon 72 G > C polymorphism was not associated with cancer risk. This suggests that this polymorphism may not be an independent risk factor for cancer in the Indian population.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-014-2114-7DOI Listing

Publication Analysis

Top Keywords

p53 codon
16
codon g > c
16
indian population
12
risk cancer
12
cancer
8
cancer risk
8
association p53
8
polymorphism risk
8
g > c polymorphism
8
cancer indian
8

Similar Publications

Decoding the general role of tRNA queuosine modification in eukaryotes.

Sci Rep

January 2025

Department of Molecular Evolution, Centro de Astrobiología (CAB), CSIC-INTA, Carretera de Ajalvir Km 4, Torrejón de Ardoz, 28850, Madrid, Spain.

Transfer RNA (tRNA) contains modified nucleosides essential for modulating protein translation. One of these modifications is queuosine (Q), which affects NAU codons translation rate. For decades, multiple studies have reported a wide variety of species-specific Q-related phenotypes in different eukaryotes, hindering the identification of a general underlying mechanism behind that phenotypic diversity.

View Article and Find Full Text PDF

We present one of the largest cohorts of TP53-pathogenic germline variants (PGVs) associated with patients with Li-Fraumeni syndrome (n = 82) with breast tumors (19 to 76 y; median age: 35). Most had missense variants (77%), followed by large gene rearrangements (LGRs; 12%), truncating (6%), and splice-site (5%) variants. Twenty-one unique germline missense variants were found, with hotspots at codons 175, 181, 245, 248, 273, 334, and 337.

View Article and Find Full Text PDF

Readthrough of a translation termination codon is regulated by ribosomal A site recognition and insertion of near-cognate tRNAs. Small molecules exist that mediate incorporation of amino acids at the stop codon and production of full-length, often functional protein but defining the actual amino acid that is incorporated remains a challenging area. Herein, we report on the development a human cell model that can be used to determine whether rules can be developed using mass spectrometry that define the type of amino acid that is placed at a premature termination codon (PTC) during readthrough mediated by an aminoglycoside.

View Article and Find Full Text PDF

The role of the most common TP53 single-nucleotide polymorphism (SNP) at codon 72, which encodes for proline (P72) or arginine (R72), in the regulation of the immune system has not yet been thoroughly explored. We found that this SNP contributes to aggravated inflammatory response in COVID-19 patients resulting from biased macrophage activation. R72-P53 inhibits mitochondrial manganese superoxide dismutase, leading to impaired reactive oxygen species scavenging, oxidation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and, consequently, its inhibition.

View Article and Find Full Text PDF

Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.

J Thorac Oncol

December 2024

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China. Electronic address:

Introduction: KRAS glycine-to-cysteine substitution at codon 12 (G12C) mutation is a well-recognized and increasingly promising therapeutic target with huge unmet clinical needs in NSCLC patients. IBI351 is a potent covalent and irreversible inhibitor of KRAS G12C. Here, we present the efficacy and safety of IBI351 from an open-label, single-arm, phase 2 pivotal study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!